- Home
- VTLE vs VSTM Comparison
VTLE vs VSTM Comparison
Compare VTLE & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- VSTM
- Stock Information
- Founded
- VTLE 2006
- VSTM 2010
- Country
- VTLE United States
- VSTM United States
- Employees
- VTLE N/A
- VSTM N/A
- Industry
- VTLE
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- VTLE
- VSTM Health Care
- Exchange
- VTLE Nasdaq
- VSTM Nasdaq
- Market Cap
- VTLE 678.2M
- VSTM 581.6M
- IPO Year
- VTLE 2011
- VSTM 2012
- Fundamental
- Price
- VTLE $17.89
- VSTM $10.28
- Analyst Decision
- VTLE Hold
- VSTM Strong Buy
- Analyst Count
- VTLE 11
- VSTM 9
- Target Price
- VTLE $25.78
- VSTM $13.38
- AVG Volume (30 Days)
- VTLE 533.2K
- VSTM 2.8M
- Earning Date
- VTLE 11-03-2025
- VSTM 11-04-2025
- Dividend Yield
- VTLE N/A
- VSTM N/A
- EPS Growth
- VTLE N/A
- VSTM N/A
- EPS
- VTLE N/A
- VSTM N/A
- Revenue
- VTLE $1,897,003,000.00
- VSTM $13,379,000.00
- Revenue This Year
- VTLE $0.55
- VSTM $88.60
- Revenue Next Year
- VTLE N/A
- VSTM $416.99
- P/E Ratio
- VTLE N/A
- VSTM N/A
- Revenue Growth
- VTLE 1.85
- VSTM 33.79
- 52 Week Low
- VTLE $12.30
- VSTM $3.46
- 52 Week High
- VTLE $36.72
- VSTM $11.25
- Technical
- Relative Strength Index (RSI)
- VTLE 59.01
- VSTM 63.93
- Support Level
- VTLE $15.56
- VSTM $7.29
- Resistance Level
- VTLE $17.57
- VSTM $10.45
- Average True Range (ATR)
- VTLE 1.01
- VSTM 0.65
- MACD
- VTLE 0.09
- VSTM 0.21
- Stochastic Oscillator
- VTLE 78.18
- VSTM 95.57
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.